Aerodynamics and deposition effects of inhaled submicron drug aerosol in airway diseases

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 7, Issue 1, 2013, Pages 49-61

  Faiyazuddin, Md ^a,b   Mujahid, Md ^b   Hussain, Talib ^b   Siddiqui, Hefazat H ^b   Bhatnagar, Aseem ^c   Khar, Roop K ^a   Ahmad, Farhan J ^a  

^a HAMDARD UNIVERSITY   (India)

^b INTEGRAL UNIVERSITY   (India)

^c INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

Aerosol effects; Airway disorders; Deposition mechanism; Lungs delivery; Pulmonary fate; Respirable submicron particles; Translocation

Indexed keywords

ATROPINE; BECLOMETASONE; BUDESONIDE; CICLESONIDE; CROMOGLYCATE DISODIUM; FENOTEROL; FLUTICASONE; FORMOTEROL; INSULIN; IPRATROPIUM BROMIDE; MOMETASONE FUROATE; PRANLUKAST; SALBUTAMOL; SALMETEROL; SURFACTANT; TERBUTALINE; TIOTROPIUM BROMIDE;

AEROSOL; ANIMAL MODEL; AQUEOUS SOLUTION; COMPETENCE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHALATIONAL DRUG ADMINISTRATION; INHALER; METERED DOSE INHALER; MOUSE; NANOEMULSION; NANOMEDICINE; NEBULIZER; NONHUMAN; PARTICLE SIZE; PATENT; POWDER; POWDER INHALER; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW;

EID: 84874910147     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221313804004691     Document Type: Review

References (160)

1. Georgakilas V, Gournis D, Tzitzios V, Pasquato L, Guldi DM, Prato M. Decorating carbon nanotubes with metal or semiconductor nanoparticles. J Mater Chem 2007; 17: 2679-94.
2. Boutonnet M, Lögdberg S, Elm Svensson E. Recent developments in the application of nanoparticles prepared from w/o microemulsions in heterogeneous catalysis. Curr Opin Colloid Interface Sci 2008; 13: 270-86.
3. De M, Ghosh PS, Rotello VM. Applications of nanoparticles in biology. Adv Mater 2008; 20: 4225-41.
4. Joachim C. To be nano or not to be nano? Nat Mater 2005; 4: 107-9.
5. Faiyazuddin Md, Ahmad S, Mustafa G, Ahmad FJ, Shakeel F. Bioanalytical approaches, bioavailability assessment and bioequivalence study for waiver drugs: In vivo and in vitro Perspective. Clinical Res Reg Affairs 2010; 27(2): 1-10.
6. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine-challenge and perspectives. Angew Chem Int Ed 2009; 48: 872-97.
7. Rieux A des, Fievez V, Garinot M, Schneider YJ, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Control Rel 2006; 116: 1-27.
8. Shi Y, Porter W, Merdan T, Li LC. Recent advances in intravenous delivery of poorly water-soluble compounds. Expert Opin Drug Deliv 2009; 6: 1261-82.
9. Cevc G, Vierl U. Nanotechnology and the transdermal route: A state of the art review and critical appraisal. J Control Rel 2010; 141: 277-99.
10. Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Nanocarriers in ocular drug delivery: An update review. Curr Pharm Des 2009; 15: 2724-50.
11. Ragab DM, Rohani S. Particle engineering strategies via crystallization for pulmonary drug delivery. Org Process Res Dev 2009; 13: 1215-23.
12. Rogueda PG, Traini D. The nanoscale in pulmonary delivery. Part 2: Formulation platforms. Expert Opin Drug Deliv 2007: 4: 607-20.
13. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009; 3: 16-20.
14. Pathak Y, Thassu D. Drug delivery nanoparticles formulation and characterization. Informa Healthcare: UK 2007.
15. Thassu D, Deleers M, Pathak Y. Nanoparticulate Drug Delivery Systems. Informa Healthcare: UK 2007.
16. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001; 47: 3-19.
17. Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: Formulating poorly water-soluble compounds. Toxicol Pathol 2008; 36: 43-8.
18. Thayer AM. Finding solutions. Chem Eng News 2010; 88: 13-8.
19. Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005; 113: 823-39.
20. Oberdörster G, Ferin J, Lehnert BE. Correlation between particle size, in vivo particle persistence, and lung injury. Environ Health Perspect 1994; 102: 173-9.
21. Zheng JY, Bosch HW. Sterile filtration of NanoCrystal™ drug formulations. Drug Dev Ind Pharm 1997; 23: 1087-93.
22. Mansour HM, Rhee YS, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomedicine 2009; 4: 299-319.
23. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol 2007; 25: 563-70.
24. Patton JS, Byron PR. Inhaling medicines: Delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007; 6: 67-74.
25. Yang W, Johnston KP, Williams RO. Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. Eur J Pharm Biopharm 2010; 75: 33-41.
26. Gill S, Lobenberg R, Ku T, Azarmi S, Roa W, Prenner EJ. Nanoparticles: Characteristics, mechanisms of action, and toxicity in pulmonary drug delivery-a review. J Biomed Nanotechnol 2007; 3: 107-19.
27. Gonda I. Systemic delivery of drugs to humans via inhalation. J Aerosol Med 2006; 19: 47-53.
28. Labiris NR, Dolovich MB. Pulmonary drug delivery Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003; 56: 600-612.
29. Yeo LY, Friend JR, McIntosh MP, Meeusen EN, Morton DA. Ultrasonic nebulization platforms for pulmonary drug delivery. Expert Opin Drug Deliv 2010; 7: 663-79.
30. Daniher DI, Zhu J. Dry powder platform for pulmonary drug delivery. Particuology 2008; 6: 225-38.
31. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004; 3: 785-96.
32. Eerdenbrugh BV, Mooter GVD, Augustijns P. Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 2008; 364: 64-75.
33. Tam JM, Engstrom JD, Ferrer D, Johnston KP. Templated open flocs of anisotropic particles for pulmonary delivery with pressurized metered dose inhalers. J Pharm Sci 2010; 99: 3150-65.
34. Ostrander KD, Bosch HW, Bondaza DM, Parry-Billings M. In: Dalby RN, Byron PR, Farr SJ, Peart J, Eds. Potential delivery advantages of spray-dried nanocrystal™ colloidal budesonide with the clickhaler®. Respiratory Drug Delivery VII 2000 (7): 447-50.
35. Mykhaylova V, Urbanetz NA. New alternative techniques to produce flowable powder for dry powder inhaler. Drug Delivery to the Lungs 2005: 33-6.
36. Chiang PC, Alsup J, Lai Y, Hu Y, Heyde B, Tung D. Evaluation of aerosol delivery of nanosuspension for pre-clinical pulmonary drug delivery. Nanoscale Res Lett 2009; 4: 254-61.
37. El-Gendy N, Berkland C. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res 2009; 26: 1752-63.
38. El-Gendy N, Berkland C. Combination nanoparticle agglomerates of fluticasone propionate and albuterol sulphate. Respiratory Drug Delivery 2010: 819-24.
39. Jacobs C, Müller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 2002; 19: 189-94.
40. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: A promising drug delivery strategy. J Pharm Pharmacol 2004; 56: 827-40.
41. Ponchel G, Montisci MJ, Dembri A, Durrer C, Duchêne D. Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract. Eur J Pharm Biopharm 1997; 44: 25-31.
42. Ghirardelli R, Bonasoro F, Porta C, Cremaschi D. Identification of particular epithelial areas and cells that transport polypeptidecoated nanoparticles in the nasal respiratory mucosa of the rabbit. Biochim Biophys Acta 1999; 1416: 39-47.
43. Bailey MM, Berkland CJ. Nanoparticle formulations in pulmonary drug delivery. Med Res Rev 2009; 29: 196-212.
44. Chow AHL, Tong HHY, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary drug delivery. Pharm Res 2007; 24: 411-37.
45. Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur J Pharm Biopharm 2006; 62: 3-16.
46. Wiedmann TS, De Castro L, Wood RW. Nebulization of NanoCrystals ™: Production of a respirable solid-in-liquid-in-air colloidal dispersion. Pharm Res 1997; 14: 112-16.
47. Ostrander KD, Bosch HW, Bondanza DM. An in vitro assessment of a nanocrystal beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. Eur J Pharm Biopharm 1999; 48: 207-15.
48. Ali HSM, York P, Blagden N. Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors. Int J Pharm 2009; 375: 107-13.
49. Burgess DJ. Injectable dispersed systems-formulation, processing, and performance. Taylor & Francis Group: USA 2005.
50. Rasenack N, Mueller BW. Micron-size drug particles: Common and novel micronization techniques. Pharm Dev Technol 2004; 9: 1-13.
51. Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res 2008; 25: 999-1022.
52. Weers JG, Tarara TE, Clark AR. Design of fine particles for pulmonary drug delivery. Expert Opin Drug Deliv 2007; 4: 297-313.
53. Rogers TL, Nelsen AC, Hu J, Brown JN, Sarkari M, Young TJ, et al. A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: Spray-freezing into liquid. Eur J Pharm Biopharm 2002; 54: 271-280.
54. Foster TP, Leatherman MW. Powder characteristics of proteins spray-dried from different spray-dryers. Drug Dev Ind Pharm 1995; 21: 1705-23.
55. Barron MK, Young TJ, Johnston KP, Williams RO. Investigation of processing parameters of spray freezing into liquid to prepare polyethylene glycol polymeric particles for drug delivery. AAPS PharmSciTech 2003; 4: E12.
56. Chen X, Young TJ, Sarkari M, Williams RO, Johnston KP. Preparation of cyclosporine a nanoparticles by evaporative precipitation into aqueous solution. Int J Pharm 2002; 242: 3-14.
57. Dickinson PA, Howells SW, Kellaway IW. Novel nanoparticles for pulmonary drug administration. J Drug Target 2001; 9: 295-302.
58. Kawashima Y, York P. Drug delivery applications of supercritical fluid technology. Adv Drug Deliv Rev 2008; 60: 297-8.
59. Zhao H, Shao L, Chen JF. High-gravity process intensification technology and application. Chem Eng J 2010; 156: 588-93.
60. Dhumal RS, Biradar SV, Paradkar AR, York P. Particle engineering using sonocrystallization: Salbutamol sulphate for pulmonary delivery. Int J Pharm 2009; 368: 129-37.
61. Panagiotou T, Fisher RJ. Form nanoparticles via controlled crystallization. Chem Eng Prog 2008; 104: 33-9.
62. Reddy LH, Sharma RK, Chuttani K, Mishra AK, Murthy RR. Etoposide incorporated tripalmitin nanoparticles with different surface charge: Formulation, characterization, radiolabeling, and biodistribution studies. AAPS J; 2004; 6: e23.
63. Kesisoglou F, Panmai S, Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007; 59: 631-44.
64. Deng Z, Xu S, Li S. Understanding a relaxation behavior in a nanoparticle suspension for drug delivery applications. Int J Pharm 2008; 351: 236-243.
65. Chan HK, Chew NYK. Novel alternative methods for the delivery of drugs for the treatment of asthma. Adv Drug Deliv Rev 2003; 55: 793-805.
66. Chougule MB, Padhi BK, Jinturkar KA, Misra A. Development of dry powder inhalers. Recent Pat Drug Deliv Formul 2007; 1: 11-21.
67. Türk M, Lietzow R. Stabilized nanoparticles of phytosterol by rapid expansion from supercritical solution into aqueous solution. AAPS PharmSciTech 2004; 5: 36-45.
68. Young TJ, Mawson S, Johnston KP, Henriksen IB, Pace GW, Mishra AK. Rapid expansion from supercritical to aqueous solution to produce submicron suspensions of water-insoluble drugs. Biotechnol Prog 2000; 16: 402-7.
69. Badens E, Majerik V, Horváth G, Szokonya L, Bosc N, Teillaud E, et al. Comparison of solid dispersions produced by supercritical antisolvent and spray-freezing technologies. Int J Pharm 2009; 377: 25-34.
70. Chiang PC, Hu Y, Blom J, Thompson D. Evaluating the suitability of using rat models for preclinical efficacy and side effects with inhaled corticosteroids nanosuspension formulations. Nanoscale Res Lett 2010; 5: 1010-9.
71. Kraft WK, Steiger B, Beussink D, Quiring JN, Fitzgerald N, Greenberg HE, et al. The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J Clin Pharmacol 2004; 44: 67-72.
72. Shrewsbury SB, Bosco AP, Uster PS. Pharmacokinetics of novel submicron budesonide dispersion for nebulized delivery in asthma. Int J Pharm 2009; 365: 12-7.
73. Keller M, Jauernig J, Lintz FC, Knoch M. Nebulizer nanosuspensions: Important device and formulation interactions. Respiratory Drug Delivery 2002: 197-206.
74. Luangkhot N, Jauernig J, Balcke A, Lintz FC, Liening-Ewert R, Stangl R, Keller M. Characterisation of salbutamol solution compared to budesonide suspensions consisting of submicron and micrometer particles in the PARI LCSTAR® and a new PARI electronic nebuliser (e-flow). Drug Delivery to the Lungs 2000; 12: 14-7.
75. Bhavna, Ahmad F, Khar R, Sultana S, Bhatnagar A. Techniques to develop and characterize nanosized formulation for salbutamol sulfate. J Mater Sci Mater Med 2009; 20: 71-6.
76. James J, Crean B, Davies M, Toon R, Jinks P, Roberts CJ. The surface characterisation and comparison of two potential submicron, sugar bulking excipients for use in low-dose, suspension formulations in metered dose inhalers. Int J Pharm 2008; 361: 209-21.
77. Jinks P. Preparation and utility of submicron lactose: A novel excipient for HFA pMDI suspensions formulations. Drug Delivery to the Lungs 2003, 14: 199-202.
78. Okuyama K, Lenggoro IW. Preparation of nanoparticles via spray route. Chem Eng Sci 2003; 58: 537-47.
79. Thybo P, Hovgaard L, Lindeløv J, Brask A, Andersen S. Scaling up the spray drying process from pilot to production scale using an atomized droplet size criterion. Pharm Res 2008; 25: 1610-20.
80. Yang ZY, Le Y, Hu TT, Shen Z, Chen JF, Yun J. Production of ultrafine sumatriptan succinate particles for pulmonary delivery. Pharm Res 2008; 25: 2012-8.
81. Engstrom J, Lai E, Ludher B, Chen B, Milner T, Williams R, et al. Formation of stable submicron protein particles by thin film freezing. Pharm Res 2008; 25: 1334-46.
82. Yang W, Tam J, Miller DA, Zhou J, McConville JT, Johnston KP, et al. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Int J Pharm 2008, 361: 177-88.
83. Rogers TL, Hu J, Yu Z, Johnston KP, Williams RO. A novel particle engineering technology: Spray-freezing into liquid. Int J Pharm 2002; 242: 93-100.
84. Vaughn JM, McConville JT, Burgess D, Peters JI, Johnston KP, Talbert RL, et al. Single dose and multiple dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm 2006; 63: 95-102.
85. Engstrom J, Tam J, Miller M, Williams RO, Johnston K. Templated open flocs of nanorods for enhanced pulmonary delivery with pressurized metered dose inhalers. Pharm Res 2009; 26: 101-17.
86. Overhoff KA, Engstrom JD, Chen B, Scherzer BD, Milner TE, Johnston KP, et al. Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly watersoluble drugs. Eur J Pharm Biopharm 2007; 65: 57-67.
87. Martín A, Cocero MJ. Micronization processes with supercritical fluids: Fundamentals and mechanisms. Adv Drug Deliv Rev 2008; 60: 339-50.
88. Pasquali I, Bettini R, Giordano F. Supercritical fluid technologies: An innovative approach for manipulating the solid-state of pharmaceuticals. Adv Drug Deliv Rev 2008; 60: 399-410.
89. Mizoe T, Ozeki T, Okada H. Preparation of drug nanoparticlecontaining microparticles using a 4-fluid nozzle spray drier for oral, pulmonary, and injection dosage forms. J Control Rel 2007; 122: 10-5.
90. Richardson CH, Matas M, Hosker H, Mukherjee R, Wong I, Chrystyn H. Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization. Pharm Res 2007; 24: 2008-17.
91. Charpentier PA, Jia M, Lucky RA. Study of the RESS process for producing beclomethasone-17, 21-dipropionate particles suitable for pulmonary delivery. AAPS PharmSciTech 2008; 9: 39-46.
92. Sinswat P, Overhoff KA, McConville JT, Johnston KP, Williams RO. Nebulization of nanoparticulate amorphous or crystalline tacrolimus-single dose pharmacokinetics study in mice. Eur J Pharm Biopharm 2008; 69: 1057-66.
93. Gupta R, Hindle M, Byron PR, Cox KA, McRae DD. Investigation of a novel condensation aerosol generator: Solute and solvent effects. Aerosol Sci Technol 2003; 37: 672-81.
94. Shakeel F, Ramadan W, Faisal MS, Rizwan Md, Faiyazuddin Md, Mustafa G, et al. Transdermal and topical delivery of antiinflammatory agents using nanoemulsion/microemulsion: An updated review. Curr Nanosci 2010; 6(2):1-15.
95. Cook RO, Pannu RK, Kellaway IW. Novel sustained release microspheres for pulmonary drug delivery. J Control Rel 2005; 104: 79-90.
96. Okamoto H, Danjo K. Application of supercritical fluid to preparation of powders of high-molecular weight drugs for inhalation. Adv Drug Deliv Rev 2008; 60: 433-46.
97. Reverchon E, Adami R. Nanomaterials and supercritical fluids. J Supercrit Fluids 2006; 37: 1-22.
98. Pasquali I, Bettini R. Are pharmaceutics really going supercritical? Int J Pharm 2008; 364: 176-87.
99. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 2010; 392:1-19.
100. Gonda I. In: Hickey AJ, Eds. Targeting by deposition. Pharmaceutical Inhalation Aerosol Technology. New York: Marcel Dekker 2004; 65-88.
101. Zeng XM, Martin AP, Marriott C, Pritchard J. The influence of carrier morphology on drug delivery by dry powder inhalers. Int J Pharm 2000; 200(1): 93-106.
102. Crowder TM. Vibration technology for active dry-powder inhalers. Pharm Technol 2004; 28: 52-61.
103. Darquenne C, Prisk GK. Deposition of inhaled particles in the human lung is more peripheral in lunar than in normal gravity. Eur J Appl Physiol 2008; 103: 687-95.
104. Matteucci ME, Hotze MA, Johnston KP, Williams RO. Drug nanoparticles by antisolvent precipitation: Mixing energy versus surfactant stabilization. Langmuir 2006; 22: 8951-9.
105. Ali R, Jain GK, Iqbal Z, Talegaonkar S, Pandit P, Sule S, et al. Development and clinical trial of nano-atropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote. Nanomedicine 2009; 5: 55-63.
106. Yang HJ, Chu GW, Zhang JW, Shen ZG, Chen JF. Micromixing efficiency in a rotating packed bed: Experiments and simulation. Ind Eng Chem Res 2005; 44: 7730-7.
107. Chen JF, Zhou MY, Shao L, Wang YY, Yun J, Chew NY, Chan HK. Feasibility of preparing nanodrugs by high-gravity reactive precipitation. Int J Pharm 2004; 269: 267-274.
108. Hu TT, Wang JX, Shen ZG, Chen JF. Engineering of drug nanoparticles by HGCP for pharmaceutical applications. Particuology 2008; 6: 239-251.
109. Hu T, Chiou H, Chan HK, Chen JF, Yun J. Preparation of inhalable salbutamol sulphate using reactive high gravity controlled precipitation. J Pharm Sci 2008; 97: 944-9.
110. Tung HH, Paul EL, Midler M, McCauley JA. Crystallization of Organic Compounds. Wiley & Sons: New York 2009.
111. Tam JM, McConville JT, Williams RO, Johnston KP. Amorphous cyclosporine nanodispersions for enhanced pulmonary deposition and dissolution. J Pharm Sci 2008; 97: 4915-33.
112. Newman SP. Dry powder inhalers for optimal drug delivery. Expert Opin Biol Ther 2004; 4: 23-33.
113. Dunbar C. Dry powder formulations for inhalation. Drug Deliv Syst Sci 2002; 2: 78-80.
114. Steckel H, Muller BW. In vitro evaluation of dry powder inhalers 1: Drug deposition of commonly used devices. Int J Pharm 1997; 154: 19-29.
115. Srichana T, Martin GP, Marriott C. Dry powder inhalers: The influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur J Pharm Sci 1998; 7: 73-80.
116. Dalby RN, Hickey AJ, Tiano SL. Medical devices for the delivery of therapeutic aerosols to the lungs. Lung Biol Health Dis 2007; 221: 417-44.
117. Chan HK. Dry powder aerosol delivery systems: Current and future research directions. J Aerosol Med 2006; 19: 21-7.
118. Hickey AJ, Crowder TM. Next generation dry powder inhalation delivery systems. Lung Biol Health Dis 2007; 221: 445-60.
119. Heng D, Cutler DJ, Chan HK, Yun J, Raper JA. What is a suitable dissolution method for drug nanoparticles? Pharm Res 2008; 25: 1696-701.
120. Son YJ, McConville JT. Development of a standardized dissolution test method for inhaled pharmaceutical formulations. Int J Pharm 2009; 382: 15-22.
121. Davies NM, Feddah MR. A novel method for assessing dissolution of aerosol inhaler products. Int J Pharm 2003; 255: 175-87.
122. Gray VA, Hickey AJ, Balmer P, Davies NM, Dunbar C, Foster TS, et al. The inhalation adhoc advisory panel for the USP performance tests of inhalation dosage forms. Phamacopeial Forum 2008; 34: 1068-74.
123. nd ed. Marcel Dekker: New York 2004.
124. USP, b601N aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers. US Pharmacopeia 2009: 32.
125. Merkus HG. Particle Size Measurements: Fundamentals, Practice, Quality. Springer 2008.
126. Newman SP, Wilding IR. Gamma scintigraphy: An in vivo technique for assessing the equivalence of inhaled products. Int J Pharm 1998; 170: 1-9.
127. Newman SP, Wilding IR. Imaging techniques for assessing drug delivery in man. Pharm Sci Technol Today 1999; 2: 181-9.
128. Snell NJC, Ganderton D. Assessing lung deposition of inhaled medications: Consensus statement from a workshop of the British association for lung research. Respir Med 1999; 93: 123-33.
129. Newman SP, Pitcairn GR, Hirst PH, Rankin L. Radionuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs. Adv Drug Deliv Rev 2003; 55: 851-67.
130. Videira MA, Botelho MF, Santos AC, Gouveia LF, Lima JJD, Almeida AJ. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drug Target 2002; 10: 607-13.
131. Bondesson E, Bengtsson T, Borgström L, Nilsson LE, Norrgren K, Trofast E, Wollmer P. Planar gamma scintigraphy-points to consider when quantifying pulmonary dry powder aerosol deposition. Int J Pharm 2003; 258: 227-40.
132. Eberl S, Chan HK, Daviskas E. Spect imaging for radioaerosol deposition and clearance studies. J Aerosol Med 2006; 19: 8-20.
133. Chan HK, Eberl S, Glover W. In: Swarbrick J, Eds. Radiolabelling of pharmaceutical aerosols and gamma scintigraphic imaging for lung deposition. Encyclopaedia of Pharmaceutical Technology. New York: Informa Healthcare 2006: 3094-107.
134. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 2006; 58: 1030-60.
135. Cryan SA, Sivadas N, Garcia-Contreras L. In vivo animal models for drug delivery across the lung mucosal barrier. Adv Drug Deliv Rev 2007; 59: 1133-51.
136. McConville J, Overhoff K, Sinswat P, Vaughn J, Frei B, Burgess D, et al. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm Res 2006; 23: 901-11.
137. Bosco AP, Castillo MC, Luangvala MM. A novel submicron formulation of nebulized budesonide significantly improves the fine particle fraction of drug available for inhalation from various jet nebulizers compared to a marketed budesonide suspension. J Allergy Clin Immunol 2009; 123: S156.
138. Bosco A, Armer TA, Uster PS. A submicron suspension of budesonide improves the mass of ICS delivered during early nebulization. Eur Respir J 2006; 28: 712S.
139. Schmid O, Moller W, Semmler-Behnke M, Ferron GA, Karg E, Lipka J, et al. Dosimetry and toxicology of inhaled ultrafine particles. Biomarkers 2009; 14 (1): 67-73.
140. Kreyling WG, Semmler-Behnke M, Moller W. Ultrafine particlelung interactions: Does size matter? J Aerosol Med 2006; 19: 74-83.
141. Green FHY, Schurch S, Gehr P, Lee MM. In: Gehr P, Heyder J, Eds. The role of surfactant in disease associated with particle exposure, Particle-Lung Interactions. New York: Marcel Dekker 2000: 533-76.
142. Gehr P, Blank F, Rothen-Rutishauser BM. Fate of inhaled particles after interaction with the lung surface. Paediatr Respir Rev 2006; 7 (1): S73-5.
143. Oberdörster G. In: Simeonova PP, Opopol N, Luster MI, Eds. Biokinetics and effects of nanoparticles, Nanotechnology-Toxicological Issues and environmental safety. Netherlands: Springer 2007: 15-51.
144. Geiser M, Kreyling WG. Deposition and biokinetics of inhaled nanoparticles. Part Fibre Toxicol 2010: 7.
145. Faiyazuddin Md, Ahmad S, Iqbal Z, Talegaonkar S, Ahmad FJ, Bhatnagar A, et al. Stability indicating HPTLC method for determination of terbutaline sulfate as bulk drug and from submicronized dry powder inhalers. Analytical Sciences 2010; 26:1-5.
146. Yang W, Peters JI, Williams RO. Inhaled nanoparticles-a current review. Int J Pharm 2008; 356: 239-47.
147. Borm P, Klaessig FC, Landry TD, Moudgil B, Pauluhn J, Thomas K, et al. Research strategies for safety evaluation of nanomaterials, Part V: Role of dissolution in biological fate and effects of nanoscale particles. Toxicol Sci 2006; 90: 23-32.
148. Madl AK, Pinkerton KE. Health effects of inhaled engineered and incidental nanoparticles. Crit Rev Toxicol 2009; 39: 629-58.
149. Faiyazuddin Md, Rauf A, Ahmad N, Ahmad S, Iqbal Z, Talegaonkar S, et al. A validated HPTLC method for determination of terbutaline sulfate in biological samples: Application to pharmacokinetic study. SPJ 2011; 19(3): 185-91.
150. Misra, A., Bhupal, C.M., Ganesh, S., Kumar, P.B. Aerodynamically light porous dry powder inhaler formulations for targeted pulmonary deposition. IP200600953 (2006).
151. Morton, D. Dry powder inhaler formulations comprising surfacemodified particles with anti-adherent additives. WO2006056812 (2006).
152. Wang Z, Chen JF, Le Y, Shen ZG, Yun J. Preparation of ultrafine beclomethasone dipropionate drug powder by antisolvent precipitation. Ind Eng Chem Res 2007; 46: 4839-45.
153. Sievers, R.E., Best, J.A., Stephen, P. Human powered dry powder inhaler and dry powder inhaler compositions. US2008035143 (2008).
154. Chawla, B., Paul, S. Inhaler. WO2008001132 (2008).
155. Wilson, B.R., Grant, M. Method of improving pharmaceutic properties of microparticles comprising diketopiperazine and an active agent. US20120010133 (2012).
156. Wong, W.S.F. Use of artemisnin derivatives for the treatment of asthma & COPD. US20120015922 (2012).
157. Olsson, M., Trofast, Eva. Dry powder inhaler. US20117896005 (2011).
158. Lalor, C.B., Tepper, J.S., Froland, W.A. Pharmaceutical polypeptide dry powder aerosol formulation & method of preparation. US20110284412 (2011).
159. Faiyazuddin Md, Ahmad N, Ahmad S, Iqbal Z, Talegaonkar S, Bhatnagar A, et al. Development and validation of UHPLC/ESI-QTOF-MS method for terbutaline estimations in experimental rodents: Stability effects and Plasma pharmacokinetics. Curr Pharm Anal 2012; 8(2): 1-7.
160. Faiyazuddin Md, Ahmad N, Khar R K, Bhatnagar A, Ahmad F J. Stabilized terbutaline submicron drug aerosol for deep lung deposition: Drug assay, pulmonokinetics and biodistribution by UHPLC/ESI-q-TOF-MS method. Int J Pharmaceutics 2012; http://dx.doi.org/10.1016/j.ijpharm.2012.05.007.